Save the date! We will present second quarter 2024 financial results and provide a business update on Thursday, August 1 at 4:30 PM ET via live webcast and conference call. Learn more: https://bit.ly/3WtndOL $ARDX
Ardelyx, Inc.
Biotechnology Research
Waltham, MA 14,243 followers
Translating Scientific Breakthroughs into Promise for Patients
About us
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. Community Guidelines: https://rb.gy/07ltg3
- Website
-
http://www.ardelyx.com
External link for Ardelyx, Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Waltham, MA
- Type
- Public Company
- Founded
- 2007
Locations
-
Primary
400 Fifth Avenue
210
Waltham, MA 02451, US
-
34175 Ardenwood Blvd
Fremont, CA 94555, US
-
260 E Highland Ave
Milwaukee, Wisconsin 53202, US
Employees at Ardelyx, Inc.
Updates
-
Press Release: Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines. Click to read: https://bit.ly/4f6vFdW
-
Make sure to join the Dialysis Patient Citizens Education Center as they go live on Instagram for a "Discussion on Phosphorus" on July 17th at 12:30PM ET. Set a reminder for the event here: https://bit.ly/3L9Qdo7 #kidneydisease
-
Today we announced that in an effort to preserve patient access to XPHOZAH, we have chosen not to apply for inclusion in the Centers for Medicare & Medicaid Services End-Stage Renal Disease Prospective Payment System Transitional Drug Add-on Payment Adjustment. Learn more: https://lnkd.in/eSWG59bn
-
Where will Team Ardelyx be this month? We have a whole new round up of #GI and #kidneydisease conferences we'll be attending!
-
Johannah Ruddy M.Ed, our director of patient advocacy, shares why she's proud to be part of a team that is committed to celebrating differences and embracing diversity! #ArdelyxProud #PrideMonth 🌈
-
Senators Ben Ray Luján and Marsha Blackburn have introduced the bipartisan Kidney PATIENT Act, which would delay for two years the inclusion of oral-only phosphate binding medication into the ESRD Prospective Payment System. Learn more about the bill from our partners at KCP here: https://ow.ly/ZI1w50Sho7q
Kidney Care Partners Applauds Senate Introduction of Bipartisan Kidney PATIENT Act - Kidney Care Partners
https://kidneycarepartners.org
-
Stepping up for kidney patients! Our team had an incredible time at the National Kidney Foundation's Northern California Kidney Walk this past weekend. We were honored to be among so many showing support for the kidney community! #ArdelyxProud